Key Takeaways
- Steady quarter, margin story stalled: Revenue grew 3% YoY to ₹498.4 crore, but EBITDA margin stayed flat at 13.2% as freight and professional expenses ate the 253 bps gross margin gain.
- Export push is a deliberate trade-off: With ethoxylation at peak capacity, management consciously diverted product to exports where realizations were healthier, accepting muted 6-7% domestic growth and higher freight costs in the near term.
- Textile is a tale of two markets: Domestic volumes grew 6-7% with no market share lost, but Bangladesh and Egypt exports collapsed on geopolitical and banking disruptions, dragging the segment down 12.5% YoY.
- Capacity unlock is the next catalyst: Loop reactors commissioning by early December and Reliance EO supply from Q4 should remove the ethoxylation bottleneck that has constrained the growth mix all year.
- What to watch next quarter: Whether Bangladesh orders resume as guided, whether the loop reactors actually start in December, and whether freight costs begin passing through to customers or keep compressing margins.
The Export Pivot: Why Domestic Looks Soft
- A capacity-constrained choice: With ethoxylation running at peak and EO availability limited, management saw a window to gain market share in exports at healthy realizations, so it pushed product abroad rather than into a fiercely competitive domestic market where FMCG Home Care volumes were flat and pricing pressure was intense.
- The cost of that choice: Export growth came with higher freight forwarding costs, especially on new customer accounts where Rossari initially bears freight; professional expenses also rose from global restructuring hires and Buzil employee additions, together pushing other expenses from ₹55 crore to ₹59 crore QoQ.
- New products invisible to revenue: A large number of new esters and resins produced in the last two quarters were consumed internally as hydrophobes for Unitop, so they are knocked out in intercompany sales and did not show up in external revenue to offset the domestic softness.
- The bottleneck is about to break: Loop reactors become functional by end November or early December, and Reliance has indicated additional EO volumes starting Q4; management expects enough EO to begin loop reactor production from January, after which ethoxylation capacity will no longer be a constraint.
Edward Menezes: "It is a very conscious decision to push our products more in export. The same products would have been also pushed in the local or domestic market, but I believe that we would have got lower gains."
Textile: Volume Growth, Revenue Decline
- Domestic volumes up, prices down: YoY volumes grew 6-7% with no market share lost, but raw material price drops in acetic acid, butyl acrylate, styrene and silicones pressured finished goods pricing down 6-7%, so revenue still fell.
- Bangladesh and Egypt froze: Bangladesh off-take dropped sharply in the last two months as LCs stopped coming through and banking channels seized up; Rossari voluntarily held back dispatches to avoid collection risk. Egypt was similarly slow. Together, export volumes degrew 4-5%.
- Recovery timeline: Management expects Bangladesh orders and banking lines to start normalizing over the next month or two, with the business coming back toward the end of Q3 and the receivable cycle improving by March.
- Longer-term textile play: The company is expanding its textile footprint into Vietnam, North Africa and Turkey, and adding sustainable products to its overseas offering to grow the vertical in 2025.
Edward Menezes: "Sanjesh, on the domestic front in Textiles, we have not lost any market share. In fact, YoY volumes grew, like Ketan sir just now reported, that YoY volumes grew by 6%-7%."
HPPC & Institutional Cleaning: The Growth Engine
- HPPC delivered 6% YoY growth to ₹390 crore, with exports up 32% in H1, driven by new customer wins across new and existing geographies and increased wallet share with existing partners.
- Institutional cleaning is scaling: The business won government laundry, airport cleaning and railway cleaning contracts; a product for nuclear facility cleaning has been approved in about 25 facilities in India. The segment is tracking to its ₹250 crore FY25 target, in line with the H1 run rate of ₹130 crore.
- Export geography push: HPPC exports are targeting Europe, South America, the Middle East and Turkey, with management expecting exports to continue outpacing domestic growth.
Animal Health & Nutrition: Strategy Reset
- Stable but small: The segment held at ₹24 crore in what is traditionally its weakest quarter due to the festive season.
- Strategy pivot completed: Rossari previously tried selling feed components alongside additives but dropped that approach after it hit margins; the focus is now squarely on the higher-margin additives business.
- Second-half ramp expected: Q3 and Q4 are traditionally strong, with marketing indicating 1.5x normal sales for Q3 versus Q1 or Q2; new initiatives include a premix plant and product launches in therapeutics and gut health improvers using bioprocess technology.
- Export markets targeted: Bangladesh, Nepal, Sri Lanka and the Philippines are the priority geographies for AHN exports.
Edward Menezes: "In the previous years, we had focused a bit on the feed component itself, not only on the additives but also on the feed components, but we found that this strategy was not working out well for us because we were taking a hit on the margins. We dropped that strategy of going in for selling the feed part of it."
Margins: Gross Profit Up, EBITDA Flat
- The margin walk: Gross margin improved 253 bps YoY on product mix and operational optimization, but EBITDA margin stayed at 13.2% because freight expenses from the growing export business, professional fees from global restructuring and hiring, and Buzil employee additions consumed the gain.
- Freight is the swing factor: Freight forwarding costs rose significantly in Q2, especially on new export accounts where Rossari initially bears freight; the plan is to bill customers on actual freight over time as relationships mature, with some costs already built into pricing.
- No near-term margin expansion promised: Management is focused on filling new capacities and scaling revenue first; the 13.2%-13.5% EBITDA band is the target for the current year and maybe half of next year, with further improvement only once utilization and scale reach a certain threshold.
- Pricing pressure adds drag: Raw material price declines intensified competitive pricing pressure in the domestic market during Q2, and management expects this trend to persist at similar levels.
Ketan Sablok: "My only submission is that in the current year and maybe half of next year, what we see is we need to start full utilization of our capacities, all the new products, the new initiatives that we are taking, that is the key for us to kind of meet and within that goal, the targets for the EBITDA are, if we are at the level that we have done in the first half, around that number plus minus a few basis points, I think we would be happy with that."
Capacity Expansion & CAPEX
- Dahej and Unitop projects: Both will be commissioned in phases over the coming months, targeting asset turns of 3 to 4x and serving agrochemicals, home and personal care, and specialty chemicals.
- Dahej land acquisition: A 39,101 sqm plot adjacent to the existing facility has been acquired for future manufacturing expansion.
- CAPEX budget raised: The board approved an additional ₹18.25 crore, taking the project budget to ₹146.25 crore, driven by design modifications for revised specifications and structural integrity.
- New products ready for external sale: Once additional capacities come up, esters and resins currently consumed internally will be available for sale to domestic and export markets.
- UAE entities established: Rossari Biotech Trading FZE was set up in JAFZA for trading and distribution of chemicals and consumer products for export markets; Unistar Thai Company Limited was acquired for manufacturing specialty chemicals related to core chemistries.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | 12%-13% top line growth | FY25 |
| Full-year EBITDA margin | Maintain around 13.2%-13.5% | FY25 and maybe H1 FY26 |
| Loop reactors operational | Ethoxylation capacity constraint removed | End November / early December 2024 |
| Reliance EO supply increase | Additional volumes to feed loop reactors | Starting Q4 FY25 |
| Bangladesh textile recovery | Orders and banking lines normalize | Next 1-2 months; business back toward end of Q3 |
| Bangladesh receivables improvement | Payment cycle normalizes | By March 2025 |
| Institutional cleaning revenue | ₹250 crore | FY25 |
| CAPEX commissioning | Dahej and Unitop projects phased commissioning | Q3, Q4 FY25 and Q1 FY26 |
| Asset turns on new projects | 3 to 4x | On commissioning |
| Textile segment recovery | Recovery in textile business | Next calendar year |
| AHN second-half strength | Healthy growth; Q3 at 1.5x normal sales vs Q1/Q2 | H2 FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹498.4 cr, +3% YoY |
| HPPC division revenue | ₹390 cr, +6% YoY from ₹367 cr |
| Textile Specialty Chemicals revenue | ₹84 cr, down from ₹96 cr YoY |
| Animal Health & Nutrition revenue | ₹24 cr, up from ₹20 cr YoY |
| Exports revenue | ₹130 cr, +21% YoY; exports now ~25% of overall sales |
| Gross margin | +253 bps YoY, driven by product mix and operational optimization |
| EBITDA | ₹65.9 cr, +3.6% YoY from ₹63.6 cr |
| EBITDA margin | 13.2%, stable YoY |
| PAT | ₹35.3 cr, +7.3% YoY from ₹32.9 cr |
| H1 FY25 revenue growth | ~11% YoY |
| Full-year FY25 revenue growth guidance | 12%-13% YoY |
| Full-year FY25 EBITDA margin guidance | 13.2%-13.5% |
| Institutional cleaning revenue | ₹70-₹73 cr; H1 FY25 ~₹130 cr; FY25 guidance ₹250 cr |
| Textile domestic volume growth | 6-7% YoY |
| AHN specialty additives growth | 20% YoY |
| CAPEX spent so far | ₹60-₹65 cr; similar amount to be spent over next 6 months; total project budget enhanced to up to ₹146.25 cr |
| Expected asset turnover on new capacities | 3x-4x |